Hepatocellular Carcinoma (HCC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer with liver cirrhosis, which develops following long periods of chronic liver disease. Cirrhosis is characterized by a decrease in hepatocyte proliferation, indicating exhaustion of the regenerative capacity of the liver. It increases fibrous tissue and the destruction of liver cells, which may ultimately lead to the development of cancerous nodules. Approximately 70%–90% of patients with HCC have an established background of chronic liver disease and cirrhosis, including chronic infection with hepatitis B virus (HBV), hepatitis C virus (HCV), alcoholic liver disease, and nonalcoholic steatohepatitis (NASH). Half of all cases of HCC are associated with hepatitis B virus infection, with a further 25% associated with hepatitis C virus. Unresectable HCC is clinically a heterogeneous group of patients, including those with the intermediate stage (BCLC B) and advanced stage (BCLC C).
Thelansis’s “Hepatocellular Carcinoma
(HCC) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Hepatocellular
Carcinoma (HCC) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Hepatocellular Carcinoma (HCC) across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Hepatocellular Carcinoma (HCC) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment